Business
Extension of Huntington's disease consortium
Extension of Huntington's disease consortium.
About this update from Ixico Plc
[{"type":"text","content":"\n \n \n 3 April 2023\n \n \n \n \n \n \n IXICO plc\n \n \n \n \n (\"IXICO\" or the \"Company\")\n \n \n \n \n \n \n \n \n Extension of Huntington's disease consortium worth circa £1 million \n \n \n \n \n \n IXICO plc (AIM: IXI),\n the neuroimaging Contract Research Organisation (CRO) delivering advanced AI analytical insights in neuroscience,\n is pleased to announce it has secured additional contract orders to support completion of the retrospective analysis of over 6,000 HD imaging datasets through the\n Huntington's Disease Imaging Harmonization Consortium (HD-IH),\n previously announced on 21st September 2022. \n HD is a rare, inherited neurodegenerative disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities.\n There are no existing approved disease modifying therapies for HD, nor interventions that slow disease progression.\n \n \n \n \n \n The output of the project will enable current and prospective consortium partners together with their collaborators to develop improved approaches to stratifying patients in HD clinical trials as well as increasing the precision of efficacy measurements of drugs within HD clinical trials. IXICO is delivering this analysis to the biopharma and charitable foundation consortium members using its proprietary, deep learning based, IXIQ.Ai analysis platform. Additional financial contribution has been secured from two partners, where one is a new consortium member and the other, an existing consortium member, enabling completion by June 2025.\n The consortium partners remain open for additional partners to join to benefit from the analysis already undertaken and to further accelerate completion of the project.\n \n \n \n \n \n \n \n Giulio Cerroni, Chief Executive Officer of IXICO, commented\n \n \n :\n \n \"\n \n The HD-IH consortium is working on the development of new standards for imaging in HD through the analysis and interpretation of existing HD imaging datasets.\n \n We are very excited to build additional momentum in the consortium and look forward to working closely with our existing and new partners towards the development of novel imaging tools that enable the design of more efficient HD clinical trials. \n \n \n \n \n \n \n \n \n The developm...